Cytokinetics

From Wikipedia, the free encyclopedia
Cytokinetics
TypePublic company
Nasdaq: CYTK
S&P 600 component
IndustryBiotechnology industry
Founded1997
Founders
Headquarters
South San Francisco, California
,
United States of America
Key people
  • Robert Blum (President & CEO)
  • Fady Malik (Executive VP)
  • Ching Jaw (CFO)
  • Stuart Kupfer (CMO)
  • Robert Califf (Board of Directors)[1]
Products
RevenueIncrease$ 56 Million(2020)[2]
Websitewww.cytokinetics.com

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

History[]

Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF.[3] Operations began in 1998.

Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins.[3] Eventually, the company narrowed its focus to the mechanics of muscle biology.[3] Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients suffering from cardiovascular and neuromuscular diseases.[4][5]

In 2004 the company completed its initial public offering (IPO).[6]

In January 2007, Cytokinetics named Robert I. Blum as President and CEO.[7] Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.[8]

In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.[9]

In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.[10]

Products[]

Omecamtiv mecarbil, a cardiac muscle activator for the potential treatment of heart failure.[11][12] In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction.[13] Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times.[3] In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021 and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil. [14][15]

Reldesemtiv (previously known as CK-2127107), is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS. [16]

Aficamten (previously known as CK-3773274), is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).[4][17]

References[]

  1. ^ "Former FDA head Gottlieb joins Pfizer board". Biopharmdive.
  2. ^ "Cytokinetics Revenue 2006-2021 | CYTK".
  3. ^ a b c d "Cytokinetics: Keeping Its Sights On Independence". Life Science Leader. Retrieved 2020-06-24.{{cite web}}: CS1 maint: url-status (link)
  4. ^ a b "Myokardia posts positive phase III for mavacamten". www.bioworld.com. Retrieved 2020-07-06.
  5. ^ "3 Biotech Stocks Surging on Positive Results". finance.yahoo.com. Retrieved 2020-07-06.
  6. ^ "Cytokinetics Inc (CYTK) IPO." Nasdaq. 29 Apr 2004
  7. ^ "New CEO at Cytokinetics." San Francisco Business Times. 22 Jan 2007. [1]
  8. ^ "Cytokinetics: Keeping Its Sights On Independence". www.lifescienceleader.com. Retrieved 2020-11-19.
  9. ^ "Astellas bites off $490M deal to develop muscle drugs with Cytokinetics". FierceBiotech. Retrieved 2020-10-28.
  10. ^ "Cytokinetics nabs Chinese partner, up to $450M as CV becomes company focus". Endpoints News. Retrieved 2020-10-22.
  11. ^ Penberthy, W T. "Omencamtiv Mecarbil Improves Symptoms in Patients with Moderate to Severe Heart Failure." MD Magazine. 18 Sept 2016. [2]
  12. ^ Casey, T. "Oral heart failure medication proves safe, effective in Phase 2 trial." Cardiovascular Business. 5 Dec 2015. [3]
  13. ^ "Novel myosin activator for HFrEF nets FDA fast track designation". www.healio.com. Retrieved 2020-08-27.
  14. ^ "Amgen terminates collaboration with Cytokinetics on 2 experimental heart drugs". www.spglobal.com. Retrieved 2021-04-23.
  15. ^ "Amgen kicks heart failure med back to Cytokinetics after 'GALACTIC' flop". FierceBiotech. Retrieved 2021-04-23.
  16. ^ MSc, Margarida Azevedo. "Reldesemtiv (Formerly CK-2127107) - ALS News Today". Retrieved 2021-12-02.
  17. ^ "Healthy data for Cytokinetics' HCM candidate". www.ddn-news.com. Retrieved 2020-07-09.

External links[]

Official website

Retrieved from ""